Dendreon (DNDNQ) Stock Price, News & Analysis

Company Overview

Dendreon Corporation is a biotechnology company focused on the development and commercialization of novel immunotherapies for oncology. Established in the early 1990s, the company pioneered the field of therapeutic cancer vaccines and brought the first FDA-approved autologous cellular immunotherapy to market. Over its history, Dendreon has built expertise in cell processing, patient-specific manufacturing, and regulatory affairs, positioning itself as a specialist in personalized cancer treatment.

The company’s flagship product, Provenge (sipuleucel-T), is designed for men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Provenge harnesses the body’s own immune system by collecting a patient’s antigen-presenting cells, activating them ex vivo with a prostate antigen target, and reintroducing them to stimulate an antitumor response. In addition to Provenge, Dendreon maintains a pipeline of next-generation immuno-oncology candidates and continues to explore combination approaches to enhance efficacy across various tumor types.

Dendreon operates a network of manufacturing and distribution facilities across the United States to ensure timely supply and delivery of personalized therapies. The company serves oncologists and treatment centers nationwide, supporting both urban and regional healthcare providers with specialized logistics and patient support services. Through strategic partnerships and collaborations, Dendreon seeks to expand its reach and accelerate the development of its pipeline in North America and beyond.

Guided by a seasoned executive leadership team with extensive backgrounds in biotechnology, clinical development, and commercial operations, Dendreon remains committed to advancing immunotherapy innovation. The management team focuses on optimizing manufacturing efficiencies, enhancing patient access, and pursuing regulatory approvals for new indications, all with the goal of improving outcomes for cancer patients worldwide.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DNDNQ Stock Analysis - Frequently Asked Questions

How were Dendreon's earnings last quarter?

Dendreon Corporation (OTCMKTS:DNDNQ) released its earnings results on Monday, November, 10th. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.10) by $0.04. The business's revenue was up 7.5% compared to the same quarter last year.

How do I buy shares of Dendreon?

Shares of DNDNQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/10/2014
• Today: 7/13/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:DNDNQ
• Previous Symbol: NASDAQ:DNDN
• CIK: N/A
• Web: www.dendreon.com
• Phone: +1-206-2197815
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A